“Today’s passage of the Inflation Reduction Act by the U.S. House of Representatives represents progress for the more than 3 million people on Medicare who use insulin, but we need to do more to ensure insulin affordability for everyone.  

The removal of the $35 per month cap for commercial plans by the Senate leaves millions of Americans, including more than 1.6 million people with type 1 diabetes, facing inflated prices of a drug they need every day to stay alive.   

JDRF stands firm in believing that more must be done and will continue to urge Congress to reconsider the INSULIN ACT to ensure that everyone who needs insulin has access regardless of insurance status.”

-JDRF

For more information from JDRF on the Inflation Reduction Act please visit: www.jdrf.org/blog/2022/08/12/inflation-reduction-act/